Abstract
In 1960s, Rosenberg discovered the anticancer activity of cisplatin, and heralded a new era of anticancer drug research based on metallopharmaceuticals. During the past 40 years, carboplatin, nedaplatin, oxaliplatin, eptaplatin, lobaplatin and dicycloplatin have been successfully developed. Although some results were achieved for platinum anticancer drugs, some problems often limited their clinical use by severe toxic side-effects, as well as the intrinsic and acquired resistance possessed by various cancers. In order to solve these problems, new metal-based anticancer drugs were started to found. Based on the similarity of structural and chemical properties between platinum(Ⅱ) and palladium(Ⅱ) complexes, palladium(Ⅱ) complexes as the potential antitumor drug have become an attractive field. This review summarized the current development of palladium(Ⅱ) complexes as potential antitumor agents, and the structure-activity relationship were studied, which will be valuable for guiding the synthesis of new type palladium(Ⅱ) anticancer drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
